| 1 | Oseltamivir Reduces 30-Day Mortality in Older Adults With Influenza: A Pooled Analysis From the 2012–2019 Serious Outcomes Surveillance Network of the Canadian Immunization Research Network | 0.8 | 4 | Citations (PDF) |
| 2 | Influenza A virus interferes with respiratory syncytial virus in mice and reconstituted human airway epithelium | 3.6 | 1 | Citations (PDF) |
| 3 | Vaccine Development for Human Pneumoviruses | 2.9 | 7 | Citations (PDF) |
| 4 | In Silico Analysis of Mechanisms of Maribavir-Induced Inhibition and Drug Resistance Mutations in pUL97 Kinase Structural Prediction with AlphaFold2 | 3.2 | 0 | Citations (PDF) |
| 5 | Metavac-RSV mucosal bivalent vaccine candidate protects cotton rats against pneumoviruses and is produced using serum-free cell culture in bioreactor | 5.3 | 0 | Citations (PDF) |
| 6 | Long COVID Symptom Management Through Self-Care and Nonprescription Treatment Options: A Narrative Review | 2.9 | 0 | Citations (PDF) |
| 7 | The impact of trained immunity in respiratory viral infections | 6.8 | 5 | Citations (PDF) |
| 8 | Management of Cytomegalovirus Infections in the Era of the Novel Antiviral Players, Letermovir and Maribavir | 2.4 | 18 | Citations (PDF) |
| 9 | Mucosal bivalent live attenuated vaccine protects against human metapneumovirus and respiratory syncytial virus in mice | 5.3 | 17 | Citations (PDF) |
| 10 | Viral interference between severe acute respiratory syndrome coronavirus 2 and influenza A viruses | 4.4 | 21 | Citations (PDF) |
| 11 | Predicting major clinical events among Canadian adults with laboratory-confirmed influenza infection using the influenza severity scale | 3.4 | 2 | Citations (PDF) |
| 12 | Influence of letermovir treatment on gut inflammation in people living with HIV on antiretroviral therapy: protocol of the open-label controlled randomised CIAO study | 1.9 | 3 | Citations (PDF) |
| 13 | Viral Fitness of Baloxavir-Resistant Recombinant Influenza B/Victoria- and B/Yamagata-like Viruses Harboring the I38T PA Change, In Vitro, Ex Vivo and in Guinea Pigs | 3.8 | 3 | Citations (PDF) |
| 14 | Leveraging Influenza Virus Surveillance From 2012 to 2015 to Characterize the Burden of Respiratory Syncytial Virus Disease in Canadian Adults ≥50 Years of Age Hospitalized With Acute Respiratory Illness | 0.8 | 18 | Citations (PDF) |
| 15 | Infection‐induced seroconversion and seroprevalence of SARS‐CoV‐2 among a cohort of children and youth in Montreal, Canada | 3.4 | 3 | Citations (PDF) |
| 16 | Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN) | 3.1 | 13 | Citations (PDF) |
| 17 | Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19 | 2.1 | 4 | Citations (PDF) |
| 18 | Viral Interference between Respiratory Viruses | 3.8 | 252 | Citations (PDF) |
| 19 | Influenza A(H1N1)pdm09 Virus but Not Respiratory Syncytial Virus Interferes with SARS-CoV-2 Replication during Sequential Infections in Human Nasal Epithelial Cells | 3.2 | 48 | Citations (PDF) |
| 20 | Single-cell transcriptomics of the ventral posterolateral nucleus-enriched thalamic regions from HSV-1-infected mice reveal a novel microglia/microglia-like transcriptional response | 9.0 | 26 | Citations (PDF) |
| 21 | Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay | 3.1 | 12 | Citations (PDF) |
| 22 | The REinfection in COVID‐19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers | 3.4 | 21 | Citations (PDF) |
| 23 | In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes | 3.8 | 6 | Citations (PDF) |
| 24 | Generation and Characterization of Drug-Resistant Influenza B Viruses Selected In Vitro with Baloxavir Acid | 3.0 | 5 | Citations (PDF) |
| 25 | A Candidate Therapeutic Monoclonal Antibody Inhibits Both HRSV and HMPV Replication in Mice | 3.4 | 12 | Citations (PDF) |
| 26 | Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine | 4.9 | 10 | Citations (PDF) |
| 27 | Human Respiratory Syncytial Virus-Induced Immune Signature of Infection Revealed by Transcriptome Analysis of Clinical Pediatric Nasopharyngeal Swab Samples | 3.8 | 7 | Citations (PDF) |
| 28 | Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: A mini‐review | 6.8 | 10 | Citations (PDF) |
| 29 | RSV and HMPV Infections in 3D Tissue Cultures: Mechanisms Involved in Virus-Host and Virus-Virus Interactions | 3.2 | 47 | Citations (PDF) |
| 30 | Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases | 3.8 | 3 | Citations (PDF) |
| 31 | Genetics of symptom remission in outpatients with COVID-19 | 3.4 | 7 | Citations (PDF) |
| 32 | Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet | 4.1 | 13 | Citations (PDF) |
| 33 | Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib | 4.3 | 21 | Citations (PDF) |
| 34 | Microglia are involved in phagocytosis and extracellular digestion during Zika virus encephalitis in young adult immunodeficient mice | 9.0 | 26 | Citations (PDF) |
| 35 | Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial | 23.4 | 248 | Citations (PDF) |
| 36 | A novel bioluminescent herpes simplex virus 1 for in vivo monitoring of herpes simplex encephalitis | 3.4 | 6 | Citations (PDF) |
| 37 | Pandemics Throughout History | 3.9 | 560 | Citations (PDF) |
| 38 | Replication and transmission of an influenza A(H3N2) virus harboring the polymerase acidic I38T substitution, in guinea pigs. | 3.3 | 6 | Citations (PDF) |
| 39 | Avian Cell Line DuckCelt®-T17 Is an Efficient Production System for Live-Attenuated Human Metapneumovirus Vaccine Candidate Metavac® | 2.9 | 12 | Citations (PDF) |
| 40 | Cytomegalovirus Seropositivity Is Associated With Increased Microbial Translocation in People Living With Human Immunodeficiency Virus and Uninfected Controls | 5.2 | 47 | Citations (PDF) |
| 41 | Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection | 3.1 | 13 | Citations (PDF) |
| 42 | In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses | 3.2 | 32 | Citations (PDF) |
| 43 | An Early Microglial Response Is Needed To Efficiently Control Herpes Simplex Virus Encephalitis | 3.6 | 34 | Citations (PDF) |
| 44 | Effects of Different Drug Combinations in Immunodeficient Mice Infected with an Influenza A/H3N2 Virus | 3.8 | 9 | Citations (PDF) |
| 45 | Hypersusceptibility of Human Cytomegalovirus to Foscarnet Induced by Mutations in Helices K and P of the Viral DNA Polymerase | 4.1 | 4 | Citations (PDF) |
| 46 | Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice | 3.8 | 19 | Citations (PDF) |
| 47 | Engineering of Live Chimeric Vaccines against Human Metapneumovirus | 3.0 | 20 | Citations (PDF) |
| 48 | Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis | 16.8 | 95 | Citations (PDF) |
| 49 | Modified cyclodextrins as broad-spectrum antivirals | 10.9 | 180 | Citations (PDF) |
| 50 | Frailty Hinders Recovery From Influenza and Acute Respiratory Illness in Older Adults | 3.8 | 45 | Citations (PDF) |
| 51 | Evaluation of pre- and post-fusion Human metapneumovirus F proteins as subunit vaccine candidates in mice | 3.1 | 15 | Citations (PDF) |
| 52 | Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization | 3.8 | 15 | Citations (PDF) |
| 53 | Characterization of cellular transcriptomic signatures induced by different respiratory viruses in human reconstituted airway epithelia | 3.4 | 40 | Citations (PDF) |
| 54 | The Val430Ile neuraminidase (NA) substitution, identified in influenza B virus isolates, impacts the catalytic 116Arg residue causing reduced susceptibility to NA inhibitors | 3.8 | 3 | Citations (PDF) |
| 55 | Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN) | 3.1 | 38 | Citations (PDF) |
| 56 | Antiviral Agents in Development for Zika Virus Infections | 4.2 | 64 | Citations (PDF) |
| 57 | Strain-Dependent Impact of G and SH Deletions Provide New Insights for Live-Attenuated HMPV Vaccine Development | 2.9 | 18 | Citations (PDF) |
| 58 | Synergistic PA and HA mutations confer mouse adaptation of a contemporary A/H3N2 influenza virus | 3.4 | 18 | Citations (PDF) |
| 59 | Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPD | 1.0 | 89 | Citations (PDF) |
| 60 | Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance | 3.8 | 95 | Citations (PDF) |
| 61 | OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes | 5.3 | 36 | Citations (PDF) |
| 62 | Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis | 3.8 | 17 | Citations (PDF) |
| 63 | Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada | 3.8 | 7 | Citations (PDF) |
| 64 | Design and Validation with Influenza A Virus of an Aerosol Transmission Chamber for Ferrets | 2.9 | 7 | Citations (PDF) |
| 65 | Human metapneumovirus activates NOD-like receptor protein 3 inflammasome via its small hydrophobic protein which plays a detrimental role during infection in mice | 4.4 | 26 | Citations (PDF) |
| 66 | Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures | 4.9 | 58 | Citations (PDF) |
| 67 | The recruitment of peripheral blood leukocytes to the brain is delayed in susceptible BALB/c compared to resistant C57BL/6 mice during herpes simplex virus encephalitis | 1.6 | 4 | Citations (PDF) |
| 68 | Novel antiviral compounds and combination therapy for influenza viruses | 0.2 | 0 | Citations (PDF) |
| 69 | Herpes simplex encephalitis in adult patients with MASP-2 deficiency | 4.4 | 22 | Citations (PDF) |
| 70 | Influenza virus epidemiology: a permanent vaccine challenge | 0.2 | 0 | Citations (PDF) |
| 71 | The Nonstructural NS1 Protein of Influenza Viruses Modulates
<i>TP53</i>
Splicing through Host Factor CPSF4 | 3.6 | 27 | Citations (PDF) |
| 72 | In Vitro Properties and Virulence of Contemporary Recombinant Influenza B Viruses Harboring Mutations of Cross-Resistance to Neuraminidase Inhibitors | 3.2 | 10 | Citations (PDF) |
| 73 | Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains | 3.8 | 61 | Citations (PDF) |
| 74 | Molecular Pathway of Influenza Pan-neuraminidase Inhibitor Resistance in an Immunocompromised Patient | 1.9 | 6 | Citations (PDF) |
| 75 | HUMAN PARAINFLUENZA 2 RELATED ILLNESS AND A DEATH IN A GROUP OF CAPTIVE WESTERN LOWLAND GORILLAS (GORILLA GORILLA GORILLA) | 0.6 | 0 | Citations (PDF) |
| 76 | Novel antiviral compounds and combination therapy for influenza viruses | 0.2 | 0 | Citations (PDF) |
| 77 | Impact of R152K and R368K neuraminidase catalytic substitutions on in vitro properties and virulence of recombinant A(H1N1)pdm09 viruses | 3.8 | 7 | Citations (PDF) |
| 78 | Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network) | 3.1 | 57 | Citations (PDF) |
| 79 | Protease‐activated receptor 1 inhibition protects mice against thrombin‐dependent respiratory syncytial virus and human metapneumovirus infections | 6.3 | 20 | Citations (PDF) |
| 80 | Resource utilization and cost of influenza requiring hospitalization in Canadian adults: A study from the serious outcomes surveillance network of the Canadian Immunization Research Network | 3.4 | 33 | Citations (PDF) |
| 81 | Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus | 3.2 | 28 | Citations (PDF) |
| 82 | Comparison of early and recent influenza A(H1N1)pdm09 isolates harboring or not the H275Y neuraminidase mutation, in vitro and in animal models | 3.8 | 3 | Citations (PDF) |
| 83 | The quest for a nanoparticle-based vaccine inducing broad protection to influenza viruses | 3.6 | 22 | Citations (PDF) |
| 84 | Both IRF3 and especially IRF7 play a key role to orchestrate an effective cerebral inflammatory response in a mouse model of herpes simplex virus encephalitis | 1.6 | 28 | Citations (PDF) |
| 85 | Predominant role of IPS-1 over TRIF adaptor proteins in early innate immune response against Zika virus in mice | 3.3 | 9 | Citations (PDF) |
| 86 | Evaluation of anticoagulant agents for the treatment of human metapneumovirus infection in mice | 3.3 | 6 | Citations (PDF) |
| 87 | Herpesvirus DNA polymerases: Structures, functions and inhibitors | 2.6 | 81 | Citations (PDF) |
| 88 | Cell Culture Systems To Study Human Herpesvirus 6A/B Chromosomal Integration | 3.6 | 32 | Citations (PDF) |
| 89 | DNA vaccination protects mice against Zika virus-induced damage to the testes | 13.7 | 97 | Citations (PDF) |
| 90 | Burden of vaccine-preventable pneumococcal disease in hospitalized adults: A Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network study | 3.1 | 30 | Citations (PDF) |
| 91 | Drug Susceptibility and Replicative Capacity of Multidrug-Resistant Recombinant Human Cytomegalovirus Harboring Mutations in
UL56
and
UL54
Genes | 4.1 | 20 | Citations (PDF) |
| 92 | A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir | 0.8 | 46 | Citations (PDF) |
| 93 | The combination of oseltamivir with azithromycin does not show additional benefits over oseltamivir monotherapy in mice infected with influenza A(H1N1)pdm2009 virus | 3.7 | 10 | Citations (PDF) |
| 94 | The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness | 3.8 | 11 | Citations (PDF) |
| 95 | Droplet digital PCR to investigate quasi‐species at codons 119 and 275 of the A(H1N1)pdm09 neuraminidase during zanamivir and oseltamivir therapies | 3.7 | 3 | Citations (PDF) |
| 96 | The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People | 3.8 | 157 | Citations (PDF) |
| 97 | Influenza vaccine effectiveness against influenza-related hospitalization during a season with mixed outbreaks of four influenza viruses: a test-negative case-control study in adults in Canada | 2.6 | 22 | Citations (PDF) |
| 98 | Protective role of CX3CR1 signalling in resident cells of the central nervous system during experimental herpes simplex virus encephalitis | 3.3 | 14 | Citations (PDF) |
| 99 | Mutations in the fusion protein heptad repeat domains of human metapneumovirus impact on the formation of syncytia | 3.3 | 14 | Citations (PDF) |
| 100 | In vitro and in vivo evidence of a potential A(H1N1)pdm09 antigenic drift mediated by escape mutations in the haemagglutinin Sa antigenic site | 3.3 | 11 | Citations (PDF) |
| 101 | A Cluster of Three Cases ofHantavirusPulmonary Syndrome among Canadian Military Personnel | 4.9 | 5 | Citations (PDF) |
| 102 | Structural Insight into NS5 of Zika Virus Leading to the Discovery of MTase Inhibitors | 15.0 | 56 | Citations (PDF) |
| 103 | Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management | 3.4 | 144 | Citations (PDF) |
| 104 | The E119D neuraminidase mutation identified in a multidrug-resistant influenza A(H1N1)pdm09 isolate severely alters viral fitness in vitro and in animal models | 3.8 | 16 | Citations (PDF) |
| 105 | A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology | 1.4 | 106 | Citations (PDF) |
| 106 | Impact of a large deletion in the neuraminidase protein identified in a laninamivir‐selected influenza A/Brisbane/10/2007 (H3N2) variant on viral fitness in vitro and in ferrets | 3.4 | 5 | Citations (PDF) |
| 107 | Novel Method Based on Real-Time Cell Analysis for Drug Susceptibility Testing of Herpes Simplex Virus and Human Cytomegalovirus | 4.0 | 34 | Citations (PDF) |
| 108 | Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories | 3.1 | 72 | Citations (PDF) |
| 109 | Both Cerebral and Hematopoietic Deficiencies in CCR2 Result in Uncontrolled Herpes Simplex Virus Infection of the Central Nervous System in Mice | 2.3 | 9 | Citations (PDF) |
| 110 | Innate immune response during herpes simplex virus encephalitis and development of immunomodulatory strategies | 6.8 | 39 | Citations (PDF) |
| 111 | Effect of In Vitro Syncytium Formation on the Severity of Human Metapneumovirus Disease in a Murine Model | 2.3 | 13 | Citations (PDF) |
| 112 | Infiltration Pattern of Blood Monocytes into the Central Nervous System during Experimental Herpes Simplex Virus Encephalitis | 2.3 | 31 | Citations (PDF) |
| 113 | E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient | 3.8 | 62 | Citations (PDF) |
| 114 | Contrasting Effects of W781V and W780V Mutations in Helix N of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Antiviral Drug Susceptibility | 3.6 | 15 | Citations (PDF) |
| 115 | Intrahost Dynamics of Antiviral Resistance in Influenza A Virus Reflect Complex Patterns of Segment Linkage, Reassortment, and Natural Selection | 4.4 | 66 | Citations (PDF) |
| 116 | Adjuvant effect of the human metapneumovirus (HMPV) matrix protein in HMPV subunit vaccines | 3.3 | 21 | Citations (PDF) |
| 117 | Heterosubtypic Protection Conferred by the Human Monoclonal Antibody PN-SIA28 against Influenza A Virus Lethal Infections in Mice | 4.1 | 3 | Citations (PDF) |
| 118 | Optimization of Droplet Digital PCR from RNA and DNA extracts with direct comparison to RT-qPCR: Clinical implications for quantification of Oseltamivir-resistant subpopulations | 1.6 | 130 | Citations (PDF) |
| 119 | Valacyclovir combined with artesunate or rapamycin improves the outcome of herpes simplex virus encephalitis in mice compared to antiviral therapy alone | 3.8 | 43 | Citations (PDF) |
| 120 | Cytomegalovirus quantification in plasma with Abbott RealTime CMV and Roche Cobas Amplicor CMV assays | 1.6 | 13 | Citations (PDF) |
| 121 | Targeted Proteomics of Human Metapneumovirus in Clinical Samples and Viral Cultures | 6.5 | 36 | Citations (PDF) |
| 122 | Permissive changes in the neuraminidase play a dominant role in improving the viral fitness of oseltamivir-resistant seasonal influenza A(H1N1) strains | 3.8 | 17 | Citations (PDF) |
| 123 | Impact of the H275Y and I223V Mutations in the Neuraminidase of the 2009 Pandemic Influenza Virus In Vitro and Evaluating Experimental Reproducibility | 2.3 | 53 | Citations (PDF) |
| 124 | Phenotypic Evaluation of Previously Uncharacterized Cytomegalovirus DNA Polymerase Sequence Variants Detected in a Valganciclovir Treatment Trial | 3.8 | 34 | Citations (PDF) |
| 125 | Antiviral drug resistance in herpesviruses other than cytomegalovirus | 6.8 | 141 | Citations (PDF) |
| 126 | Oseltamivir–zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses | 3.8 | 15 | Citations (PDF) |
| 127 | Impact of Potential Permissive Neuraminidase Mutations on Viral Fitness of the H275Y Oseltamivir-Resistant Influenza A(H1N1)pdm09 VirusIn Vitro, in Mice and in Ferrets | 3.6 | 52 | Citations (PDF) |
| 128 | Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines | 3.1 | 16 | Citations (PDF) |
| 129 | Evolution of Oseltamivir Resistance Mutations in Influenza A(H1N1) and A(H3N2) Viruses during Selection in Experimentally Infected Mice | 4.1 | 30 | Citations (PDF) |
| 130 | Epitope mapping of the 2009 pandemic and the A/Brisbane/59/2007 seasonal (H1N1) influenza virus haemagglutinins using mAbs and escape mutants | 3.3 | 16 | Citations (PDF) |
| 131 | Characterization of Drug-Resistant Influenza Virus A(H1N1) and A(H3N2) Variants SelectedIn Vitrowith Laninamivir | 4.1 | 50 | Citations (PDF) |
| 132 | Human metapneumovirus viral load is an important risk factor for disease severity in young children | 3.0 | 36 | Citations (PDF) |
| 133 | Randomized Controlled Ferret Study to Assess the Direct Impact of 2008–09 Trivalent Inactivated Influenza Vaccine on A(H1N1)pdm09 Disease Risk | 2.3 | 23 | Citations (PDF) |
| 134 | Recent developments with live‐attenuated recombinant paramyxovirus vaccines | 6.8 | 25 | Citations (PDF) |
| 135 | Genetic diversity and molecular evolution of the major human metapneumovirus surface glycoproteins over a decade | 3.0 | 48 | Citations (PDF) |
| 136 | Host and Viral Factors Affecting Clinical Performance of a Rapid Diagnostic Test for Respiratory Syncytial Virus in Hospitalized Children | 2.0 | 25 | Citations (PDF) |
| 137 | Analysis of HHV-6 mutations in solid organ transplant recipients at the onset of cytomegalovirus disease and following treatment with intravenous ganciclovir or oral valganciclovir | 3.0 | 15 | Citations (PDF) |
| 138 | Influenza virus resistance to neuraminidase inhibitors | 3.8 | 328 | Citations (PDF) |
| 139 | Virus-like particle vaccine induces cross-protection against human metapneumovirus infections in mice | 3.1 | 48 | Citations (PDF) |
| 140 | Detection and management of antiviral resistance for influenza viruses | 3.4 | 55 | Citations (PDF) |
| 141 | The combination of valacyclovir with an anti-TNF alpha antibody increases survival rate compared to antiviral therapy alone in a murine model of herpes simplex virus encephalitis | 3.8 | 19 | Citations (PDF) |
| 142 | Both TRIF and IPS-1 Adaptor Proteins Contribute to the Cerebral Innate Immune Response against Herpes Simplex Virus 1 Infection | 3.6 | 38 | Citations (PDF) |
| 143 | Evaluation of Recombinant 2009 Pandemic Influenza A (H1N1) Viruses Harboring Zanamivir Resistance Mutations in Mice and Ferrets | 4.1 | 15 | Citations (PDF) |
| 144 | Novel Method Based on “En Passant” Mutagenesis Coupled with a Gaussia Luciferase Reporter Assay for Studying the Combined Effects of Human Cytomegalovirus Mutations | 4.0 | 30 | Citations (PDF) |
| 145 | Modulation of Protease Activated Receptor 1 Influences Human Metapneumovirus Disease Severity in a Mouse Model | 2.3 | 33 | Citations (PDF) |
| 146 | Comparison of Risk Factors for Human Metapneumovirus and Respiratory Syncytial Virus Disease Severity in Young Children | 3.8 | 149 | Citations (PDF) |
| 147 | Cross-reactive and Vaccine-Induced Antibody to an Emerging Swine-Origin Variant of Influenza A Virus Subtype H3N2 (H3N2v) | 3.8 | 85 | Citations (PDF) |
| 148 | Presence of Oseltamivir-Resistant Pandemic A/H1N1 Minor Variants Before Drug Therapy With Subsequent Selection and Transmission | 3.8 | 72 | Citations (PDF) |
| 149 | Effects of Different Adjuvants in the Context of Intramuscular and Intranasal Routes on Humoral and Cellular Immune Responses Induced by Detergent-Split A/H3N2 Influenza Vaccines in Mice | 3.1 | 46 | Citations (PDF) |
| 150 | The H275Y Neuraminidase Mutation of the Pandemic A/H1N1 Influenza Virus Lengthens the Eclipse Phase and Reduces Viral Output of Infected Cells, Potentially Compromising Fitness in Ferrets | 3.6 | 106 | Citations (PDF) |
| 151 | Therapeutic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H275Y Neuraminidase Mutation | 4.1 | 17 | Citations (PDF) |
| 152 | Impact of deficiency in CCR2 and CX3CR1 receptors on monocytes trafficking in herpes simplex virus encephalitis | 3.3 | 30 | Citations (PDF) |
| 153 | Modulation of TLR9 response in a mouse model of herpes simplex virus encephalitis | 3.8 | 25 | Citations (PDF) |
| 154 | Molecular and antigenic evolution of human influenza A/H3N2 viruses in Quebec, Canada, 2009–2011 | 3.0 | 26 | Citations (PDF) |
| 155 | Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis | 3.0 | 54 | Citations (PDF) |
| 156 | Cross-Lineage Influenza B and Heterologous Influenza A Antibody Responses in Vaccinated Mice: Immunologic Interactions and B/Yamagata Dominance | 2.3 | 45 | Citations (PDF) |
| 157 | Seroconversion to Seasonal Influenza Viruses after A(H1N1)pdm09 Virus Infection, Quebec, Canada | 3.8 | 6 | Citations (PDF) |
| 158 | Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010 | 3.8 | 44 | Citations (PDF) |
| 159 | Impact of Mutations at Residue I223 of the Neuraminidase Protein on the Resistance Profile, Replication Level, and Virulence of the 2009 Pandemic Influenza Virus | 4.1 | 61 | Citations (PDF) |
| 160 | Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients | 3.1 | 33 | Citations (PDF) |
| 161 | Antibody persistence and response to 2010–2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children | 3.1 | 36 | Citations (PDF) |
| 162 | Parenteral Peramivir Treatment for Oseltamivir-Resistant 2009 Pandemic Influenza A H1N1 Viruses | 3.8 | 11 | Citations (PDF) |
| 163 | Assessing the In Vitro Fitness of an Oseltamivir-Resistant Seasonal A/H1N1 Influenza Strain Using a Mathematical Model | 2.3 | 62 | Citations (PDF) |
| 164 | Comparison of Pandemic and Seasonal Influenza in the Pediatric Emergency Department | 1.1 | 16 | Citations (PDF) |
| 165 | Risk factors for hospitalization and severe outcomes of 2009 pandemic H1N1 influenza in Quebec, Canada | 3.4 | 98 | Citations (PDF) |
| 166 | Systematic review of influenza resistance to the neuraminidase inhibitors | 2.6 | 180 | Citations (PDF) |
| 167 | Generation and Characterization of Recombinant Pandemic Influenza A(H1N1) Viruses Resistant to Neuraminidase Inhibitors | 3.8 | 147 | Citations (PDF) |
| 168 | Influenza Drug Resistance | 2.3 | 74 | Citations (PDF) |
| 169 | Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet | 4.1 | 32 | Citations (PDF) |
| 170 | Design considerations in buildingin silicoequivalents of common experimental influenza virus assays | 3.1 | 37 | Citations (PDF) |
| 171 | Role of Permissive Neuraminidase Mutations in Influenza A/Brisbane/59/2007-like (H1N1) Viruses | 4.4 | 78 | Citations (PDF) |
| 172 | The 2009 Pandemic H1N1 D222G Hemagglutinin Mutation Alters Receptor Specificity and Increases Virulence in Mice but Not in Ferrets | 3.8 | 38 | Citations (PDF) |
| 173 | Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis | 2.1 | 24 | Citations (PDF) |
| 174 | Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity | 1.9 | 17 | Citations (PDF) |
| 175 | Prophylactic and therapeutic benefits of a monoclonal antibody against the fusion protein of human metapneumovirus in a mouse model | 3.8 | 43 | Citations (PDF) |
| 176 | Neurovirulence and latency of drug‐resistant clinical herpes simplex viruses in animal models | 3.7 | 15 | Citations (PDF) |
| 177 | The distinguishing features of human metapneumovirus and respiratory syncytial virus | 6.8 | 86 | Citations (PDF) |
| 178 | Effect of the Neuraminidase Mutation H274Y Conferring Resistance to Oseltamivir on the Replicative Capacity and Virulence of Old and Recent Human Influenza A(H1N1) Viruses | 3.8 | 125 | Citations (PDF) |
| 179 | Prophylactic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H274Y Neuraminidase Mutation | 4.1 | 20 | Citations (PDF) |
| 180 | Household Transmission of the 2009 Pandemic A/H1N1 Influenza Virus: Elevated Laboratory‐Confirmed Secondary Attack Rates and Evidence of Asymptomatic Infections | 5.2 | 107 | Citations (PDF) |
| 181 | Viral Pathogens Including Human Metapneumovirus Are the Primary Cause of Febrile Respiratory Illness in HIV‐Infected Adults Receiving Antiretroviral Therapy | 3.8 | 26 | Citations (PDF) |
| 182 | Association between the 2008–09 Seasonal Influenza Vaccine and Pandemic H1N1 Illness during Spring–Summer 2009: Four Observational Studies from Canada | 8.1 | 278 | Citations (PDF) |
| 183 | Oseltamivir-Resistant Pandemic A/H1N1 Virus Is as Virulent as Its Wild-Type Counterpart in Mice and Ferrets | 4.4 | 87 | Citations (PDF) |
| 184 | Contagious Period for Pandemic (H1N1) 2009 | 3.8 | 47 | Citations (PDF) |
| 185 | Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis | 3.0 | 37 | Citations (PDF) |
| 186 | Contrasting effects on ganciclovir susceptibility and replicative capacity of two mutations at codon 466 of the human cytomegalovirus UL97 gene | 3.0 | 17 | Citations (PDF) |
| 187 | Activity of the Oral Neuraminidase Inhibitor A-322278 against the Oseltamivir-Resistant H274Y (A/H1N1) Influenza Virus Mutant in Mice | 4.1 | 14 | Citations (PDF) |
| 188 | A Novel Neuraminidase Deletion Mutation Conferring Resistance to Oseltamivir in Clinical Influenza A/H3N2 Virus | 3.8 | 43 | Citations (PDF) |
| 189 | Emergence of Oseltamivir-Resistant Pandemic H1N1 Virus during Prophylaxis | 34.6 | 217 | Citations (PDF) |
| 190 | Comparison of Automated Microarray Detection with Real-Time PCR Assays for Detection of Respiratory Viruses in Specimens Obtained from Children | 4.0 | 96 | Citations (PDF) |
| 191 | The Need for Validation of Statistical Methods for Estimating Respiratory Virus-Attributable Hospitalization | 3.3 | 42 | Citations (PDF) |
| 192 | Influenza virus shedding—Excretion patterns and effects of antiviral treatment | 3.0 | 37 | Citations (PDF) |
| 193 | Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations | 3.0 | 100 | Citations (PDF) |
| 194 | Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir | 1.9 | 101 | Citations (PDF) |
| 195 | Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes | 3.8 | 61 | Citations (PDF) |
| 196 | Human respiratory syncytial virus and other viral infections in infants receiving palivizumab | 3.0 | 41 | Citations (PDF) |
| 197 | Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform | 3.1 | 180 | Citations (PDF) |
| 198 | Effect of Pretreatment with Toll‐like Receptor Agonists in a Mouse Model of Herpes Simplex Virus Type 1 Encephalitis | 3.8 | 62 | Citations (PDF) |
| 199 | Identification and Evaluation of a Highly Effective Fusion Inhibitor for Human Metapneumovirus | 4.1 | 59 | Citations (PDF) |
| 200 | Persistent Human Metapneumovirus Infection in Immunocompromised Child | 3.8 | 19 | Citations (PDF) |
| 201 | Inhibition of Human Metapneumovirus Replication by Small Interfering RNA | 1.9 | 26 | Citations (PDF) |
| 202 | The Prophylactic Administration of a Monoclonal Antibody against Human Metapneumovirus Attenuates viral Disease and Airways Hyperresponsiveness in Mice | 1.9 | 29 | Citations (PDF) |
| 203 | Human Metapneumovirus | 2.3 | 54 | Citations (PDF) |
| 204 | Tumor Necrosis Factor–α and Interleukin‐1β Play a Critical Role in the Resistance against Lethal Herpes Simplex Virus Encephalitis | 3.8 | 150 | Citations (PDF) |
| 205 | An Outbreak of Severe Respiratory Tract Infection Due to Human Metapneumovirus in a Long-Term Care Facility | 5.2 | 205 | Citations (PDF) |
| 206 | Delayed but Not Early Glucocorticoid Treatment Protects the Host during Experimental Herpes Simplex Virus Encephalitis in Mice | 3.8 | 74 | Citations (PDF) |
| 207 | Human metapneumovirus: Enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged | 3.1 | 64 | Citations (PDF) |
| 208 | Antibiotic use in children is not influenced by the result of rapid antigen detection test for the respiratory syncytial virus | 3.0 | 18 | Citations (PDF) |
| 209 | Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir | 3.8 | 62 | Citations (PDF) |
| 210 | Influenza Virus Susceptibility and Resistance to Oseltamivir | 1.9 | 155 | Citations (PDF) |
| 211 | Role of Helix P of the Human Cytomegalovirus DNA Polymerase in Resistance and Hypersusceptibility to the Antiviral Drug Foscarnet | 3.6 | 28 | Citations (PDF) |
| 212 | Pathogenicity and response to topical antiviral therapy in a murine model of acyclovir-sensitive and acyclovir-resistant herpes simplex viruses isolated from the same patient | 3.0 | 3 | Citations (PDF) |
| 213 | Multi-year study of human metapneumovirus infection at a large US Midwestern Medical Referral Center | 3.0 | 35 | Citations (PDF) |
| 214 | Longitudinal evaluation of herpes simplex virus DNA load during episodes of herpes labialis | 3.0 | 21 | Citations (PDF) |
| 215 | Human Metapneumovirus, Peru | 3.8 | 51 | Citations (PDF) |
| 216 | Treatment of respiratory virus infections | 3.8 | 66 | Citations (PDF) |
| 217 | Distribution and Clinical Impact of Human Respiratory Syncytial Virus Genotypes in Hospitalized Children over 2 Winter Seasons | 3.8 | 95 | Citations (PDF) |
| 218 | Characterization of Human Cytomegalovirus (HCMV) UL97 Mutations Found in a Valganciclovir/Oral Ganciclovir Prophylactic Trial by Use of a Bacterial Artificial Chromosome Containing the HCMV Genome | 3.8 | 26 | Citations (PDF) |
| 219 | Effect of Ribavirin and Glucocorticoid Treatment in a Mouse Model of Human Metapneumovirus Infection | 4.1 | 117 | Citations (PDF) |
| 220 | Thymidine Kinase Mutations Conferring Acyclovir Resistance in Herpes Simplex Type 1 Recombinant Viruses | 4.1 | 28 | Citations (PDF) |
| 221 | Human Metapneumovirus Infection Induces Long‐Term Pulmonary Inflammation Associated with Airway Obstruction and Hyperresponsiveness in Mice | 3.8 | 93 | Citations (PDF) |
| 222 | Characterization of Multidrug-Resistant Influenza A/H3N2 Viruses Shed during 1 Year by an Immunocompromised Child | 5.2 | 182 | Citations (PDF) |
| 223 | Impact of Neuraminidase Mutations Conferring Influenza Resistance to Neuraminidase Inhibitors in the N1 and N2 Genetic Backgrounds | 1.9 | 160 | Citations (PDF) |
| 224 | Infections by Human Coronavirus-NL in Hospitalized Children | 1.1 | 37 | Citations (PDF) |
| 225 | A Trial of Valganciclovir Prophylaxis for Cytomegalovirus Prevention in Lung Transplant Recipients | 4.5 | 93 | Citations (PDF) |
| 226 | Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis | 3.7 | 61 | Citations (PDF) |
| 227 | Human Metapneumovirus Genetic Variability, South Africa | 3.8 | 69 | Citations (PDF) |
| 228 | Analysis of Replication Kinetics of the Human Metapneumovirus in Different Cell Lines by Real-Time PCR | 4.0 | 55 | Citations (PDF) |
| 229 | Development and Validation of an Enzyme-Linked Immunosorbent Assay for Human Metapneumovirus Serology Based on a Recombinant Viral Protein | 3.1 | 46 | Citations (PDF) |
| 230 | Generation and Characterization of Recombinant Influenza A (H1N1) Viruses Harboring Amantadine Resistance Mutations | 4.1 | 178 | Citations (PDF) |
| 231 | Human Metapneumovirus | 1.1 | 42 | Citations (PDF) |
| 232 | Global Genetic Diversity of Human Metapneumovirus Fusion Gene | 3.8 | 135 | Citations (PDF) |
| 233 | Absence of Cytomegalovirus‐Resistance Mutations after Valganciclovir Prophylaxis, in a Prospective Multicenter Study of Solid‐Organ Transplant Recipients | 3.8 | 161 | Citations (PDF) |
| 234 | Human Metapneumovirus: A New Player among Respiratory Viruses | 5.2 | 186 | Citations (PDF) |
| 235 | Multiplex Real-Time PCR Assay for Detection of Influenza and Human Respiratory Syncytial Viruses | 4.0 | 138 | Citations (PDF) |
| 236 | A Reverse Genetics Study of Resistance to Neuraminidase Inhibitors in An Influenza A/H1N1 Virus | 1.9 | 80 | Citations (PDF) |
| 237 | Genetic diversity between human metapneumovirus subgroups | 2.3 | 238 | Citations (PDF) |
| 238 | Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro | 3.8 | 208 | Citations (PDF) |
| 239 | Sequence analysis of the N, P, M and F genes of Canadian human metapneumovirus strains | 2.6 | 120 | Citations (PDF) |
| 240 | Human Metapneumovirus-Associated Lower Respiratory Tract Infections among Hospitalized Human Immunodeficiency Virus Type 1 (HIV-1)-Infected and HIV-1-Uninfected African Infants | 5.2 | 117 | Citations (PDF) |
| 241 | Evaluation of Susceptibility of Human Herpesvirus 8 to Antiviral Drugs by Quantitative Real-Time PCR | 4.0 | 38 | Citations (PDF) |
| 242 | Comparative Evaluation of Real-Time PCR Assays for Detection of the Human Metapneumovirus | 4.0 | 122 | Citations (PDF) |
| 243 | Quantification of the Influenza Virus Load by Real‐Time Polymerase Chain Reaction in Nasopharyngeal Swabs of Patients Treated with Oseltamivir | 3.8 | 42 | Citations (PDF) |
| 244 | Discordant phenotypes and genotypes of Cytomegalovirus (CMV) in patients with AIDS and relapsing CMV retinitis | 2.5 | 19 | Citations (PDF) |
| 245 | Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids | 3.6 | 88 | Citations (PDF) |
| 246 | Human Metapneumovirus Infections in Hospitalized Children1 | 3.8 | 423 | Citations (PDF) |
| 247 | Characterization of 2 Influenza A(H3N2) Clinical Isolates with Reduced Susceptibility to Neuraminidase Inhibitors Due to Mutations in the Hemagglutinin Gene | 3.8 | 57 | Citations (PDF) |
| 248 | Prolonged Excretion of Amantadine-Resistant Influenza A Virus Quasi Species after Cessation of Antiviral Therapy in an Immunocompromised Patient | 5.2 | 73 | Citations (PDF) |
| 249 | Role of Picornaviruses in Flu-Like Illnesses of Adults Enrolled in an Oseltamivir Treatment Study Who Had No Evidence of Influenza Virus Infection | 4.0 | 20 | Citations (PDF) |
| 250 | Virological Features and Clinical Manifestations Associated with Human Metapneumovirus: A New Paramyxovirus Responsible for Acute Respiratory‐Tract Infections in All Age Groups | 3.8 | 579 | Citations (PDF) |
| 251 | Characterization of Human Metapneumoviruses Isolated from Patients in North America | 3.8 | 387 | Citations (PDF) |
| 252 | Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms | 19.3 | 294 | Citations (PDF) |
| 253 | Respiratory Tract Reinfections by the New Human Metapneumovirus in an Immunocompromised Child | 3.8 | 215 | Citations (PDF) |
| 254 | Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors | 3.8 | 65 | Citations (PDF) |
| 255 | Divergent evolution of hemagglutinin and neuraminidase genes in recent influenza A:H3N2 viruses isolated in Canada | 3.7 | 47 | Citations (PDF) |
| 256 | Quantification of human herpesvirus 8 by real-time PCR in blood fractions of AIDS patients with Kaposi's sarcoma and multicentric Castleman's disease | 3.7 | 42 | Citations (PDF) |
| 257 | Intranasal herpes simplex virus type 2 inoculation causes a profound thymidine kinase dependent cerebral inflammatory response in the mouse hindbrain | 3.5 | 47 | Citations (PDF) |
| 258 | Highly Reliable Heterologous System for Evaluating Resistance of Clinical Herpes Simplex Virus Isolates to Nucleoside Analogues | 3.6 | 58 | Citations (PDF) |
| 259 | Evaluation of a Rapid Optical Immunoassay for Influenza Viruses (FLU OIA Test) in Comparison with Cell Culture and Reverse Transcription-PCR | 4.0 | 81 | Citations (PDF) |
| 260 | Rate of Emergence of Cytomegalovirus (CMV) Mutations in Leukocytes of Patients with Acquired Immunodeficiency Syndrome Who Are Receiving Valganciclovir as Induction and Maintenance Therapy for CMV Retinitis | 3.8 | 127 | Citations (PDF) |
| 261 | Evaluation of the human herpesvirus 8 DNA load in blood and Kaposi's sarcoma skin lesions from AIDS Patients on highly active antiretroviral therapyAids, 2000, 14, 1907-1910 | 2.5 | 55 | Citations (PDF) |
| 262 | Rapid Antiviral Effect of Inhaled Zanamivir in the Treatment of Naturally Occurring Influenza in Otherwise Healthy Adults | 3.8 | 73 | Citations (PDF) |
| 263 | Characterization of the DNA Polymerase and Thymidine Kinase Genesof Herpes Simplex Virus Isolates from AIDS Patients in whom Acyclovirand Foscarnet Therapy Sequentially Failed | 3.8 | 97 | Citations (PDF) |
| 264 | Expression of the Late Cytomegalovirus (CMV) pp150 Transcript in Leukocytes of AIDS Patients Is Associated with a High Viral DNA Load in Leukocytes and Presence of CMV DNA in Plasma | 3.8 | 20 | Citations (PDF) |
| 265 | Human Herpesvirus 8 DNA Load in Leukocytes of Human Immunodeficiency Virus-Infected Subjects: Correlation with the Presence of Kaposi’s Sarcoma and Response to Anticytomegalovirus Therapy | 4.1 | 38 | Citations (PDF) |
| 266 | Comparative Evaluation of the Cytomegalovirus DNA Load in Polymorphonuclear Leukocytes and Plasma of Human Immunodeficiency Virus‐Infected Subjects | 3.8 | 57 | Citations (PDF) |
| 267 | Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients | 2.5 | 46 | Citations (PDF) |
| 268 | Quantitation of Cytomegalovirus: Methodologic Aspects and Clinical Applications | 16.8 | 389 | Citations (PDF) |
| 269 | Evaluation of the AMPLICOR Cytomegalovirus Test with Specimens from Human Immunodeficiency Virus-Infected Subjects | 4.0 | 41 | Citations (PDF) |
| 270 | Antiviral Susceptibilities and Analysis of UL97 and DNA Polymerase Sequences of Clinical Cytomegalovirus Isolates from Immunocompromised Patients | 3.8 | 153 | Citations (PDF) |
| 271 | A case of ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with AIDS | 2.5 | 22 | Citations (PDF) |
| 272 | Quantitation of Cytomegalovirus DNA and Characterization of Viral Gene Expression in Bronchoalveolar Cells of Infected Patients with and without Pneumonitis | 3.8 | 41 | Citations (PDF) |
| 273 | Quantitation of human cytomegalovirus glycoprotein H gene in cells using competitive PCR and a rapid fluorescence-based detection system | 1.6 | 38 | Citations (PDF) |
| 274 | Phenotypic and Genotypic Characterization of Acyclovir-Resistant Varicella-Zoster Viruses Isolated from Persons with AIDS | 3.8 | 128 | Citations (PDF) |
| 275 | The Changing Landscape of Respiratory Viruses Contributing to Hospitalizations in Quebec, Canada: Results From an Active Hospital-Based Surveillance Study | 4.8 | 18 | Citations (PDF) |
| 276 | Fitness of SARS-CoV-2 Omicron Subvariants in Respiratory and Gastrointestinal Cell Lines as Determined by Reverse-Transcription Droplet Digital PCR and Whole-Genome Sequencing | 3.8 | 0 | Citations (PDF) |
| 277 | Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3 | 6.8 | 0 | Citations (PDF) |
